AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT05470959 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Riva LC
Description: resin-modified glass ionomer
Study NCT02822209 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: EORTC QLQ-C30
Description: Questionnaire submitted at the beginning of the study. Then three more times : 3, 6 and 12 months after the start of anti-cancer therapy. The questionnaire can also be completed before the 12th month: when the care program is about to end
Study NCT02822209 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: EORTC QLQ-C30
Description: Questionnaire submitted at the beginning of the study. Then three more times : 3, 6 and 12 months after the start of anti-cancer therapy. The questionnaire can also be completed before the 12th month: when the care program is about to end
Study NCT02822209 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Satisfaction questionnaire - patient
Description: The patient will fill in a satisfaction questionnaire three times : around the third, the sixth and the twelfth month after they started an anti-cancer therapy.
Study NCT02822209 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Satisfaction questionnaire - patient
Description: The patient will fill in a satisfaction questionnaire three times : around the third, the sixth and the twelfth month after they started an anti-cancer therapy.
Study NCT02822209 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Satisfaction questionnaire - general practitioner or home nurse
Description: The general practitioner or the nurse in charge of the patient at home will fill in a satisfaction questionnaire six months after the patient started an anti-cancer therapy.
Study NCT02822209 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Satisfaction questionnaire - general practitioner or home nurse
Description: The general practitioner or the nurse in charge of the patient at home will fill in a satisfaction questionnaire six months after the patient started an anti-cancer therapy.
Study NCT02822209 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: EORTC QLQ-LC13
Description: Questionnaire submitted at the beginning of the study. Then three more times : 3, 6 and 12 months after the start of anti-cancer therapy. The questionnaire can also be completed before the 12th month: when the care program is about to end
Study NCT02822209 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: EORTC QLQ-LC13
Description: Questionnaire submitted at the beginning of the study. Then three more times : 3, 6 and 12 months after the start of anti-cancer therapy. The questionnaire can also be completed before the 12th month: when the care program is about to end
Study NCT02394964 — intervention group
Intervention type: OTHER
Intervention: Sample Collection
Description: Sample collection of blood, stool, and buccal and skin swab samples will be collected at baseline, week 4, and week 8
Study NCT01172639 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Methotrexate
Description: Methotrexate tablet
Study NCT01172639 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Sulfasalazine
Description: Sulfasalazine tablet
Study NCT01172639 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Leflunomide
Description: Leflunomide tablet
Study NCT01172639 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Prednisone
Description: Prednisone tablet
Study NCT05469113 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Repaglinide
Description: Administered orally.
Study NCT05469113 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Selpercatinib
Description: Administered orally.
Study NCT02798913 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Short DAPT
Description: acetylsalicylic acid 100 mg/day life-long + clopidogrel 75 mg/day for 3 months
Study NCT02798913 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Long DAPT
Description: acetylsalicylic acid 100 mg/day life-long + clopidogrel 75 mg/day for 12 months
Study NCT04011397 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise intervention
Description: Exercise intervention (reduced-exertion, high-intensity interval training) delivered within an NHS setting. Consisted 10 min of cycle ergometry (inclusive of warm-up and cool down) including very brief maximal cycle sprints.
Study NCT04011397 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Usual care
Description: Members of a multi-disciplinary team including a consultant, diabetes specialist nurse, clinical psychologist, physiotherapist, and dietician worked together to promote patient self-management. Care was tailored to the specific circumstances of each patient after initial assessment and focussed on weight management, dietary education, behavioural therapy, and supported pharmacotherapy initiation as appropriate.
Study NCT02764177 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Protein drink
Description: The protein drink was administered during this trial
Study NCT02764177 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Carbohydrate drink
Description: The carbohydrate drink was administered in this trial
Study NCT03487263 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: IC14
Description: chimeric monoclonal antibody against human IC14
Study NCT02866071 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ketamine Hydrochloride
Description: 50mg IN Ketamine Hydrochloride
Study NCT02866071 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo-Comparator
Description: 50mg IN Placebo
Study NCT04651556 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Magnesium Sulfate & bupivacaine
Description: intraperitoneal instillation of a combination of Magnesium sulphate with bupivacaine
Study NCT04651556 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: paracetamol & ketorolac
Description: parenteral analgesics
Study NCT01624597 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: In-vehicle video feedback
Description: An in-vehicle video system will record driving errors and safety behaviors. A light on the system will blink to let the participant know that a driving error has been recorded. Parents will receive a weekly report card.
Study NCT01624597 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Parent communication
Description: Parents will receive instruction in teaching and effective communication about driving skills and driving safety. The intervention includes driving goals for teen drivers and parent communication strategies.
Study NCT02204319 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Cold laser
Description: Erchonia Corporation variable frequency pulsed wave low level laser device employing three independent 7 milliWatt, 635 nanometer red light diodes mounted in a hand-held device and is a variable frequency pulsed wave device.
Study NCT00383747 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: transdermal nicotine patch
Description: 14mg transdermal nicotine application
Study NCT00383747 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Transdermal Nicotine Patch
Description: 14mg transdermal nicotine application
Study NCT03432650 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bupivacaine + dexamethasone
Description: Anesthetic that will help treat pain and sensation after hip arthroscopy
Study NCT03432650 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Ultrasound
Description: Ultrasound will help guide the anesthesiologist in performing the nerve block
Study NCT04636957 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ciprofloxacin-Fluocinolone Acetonide, 0.3%-0.025% Otic Solution
Description: 0.25mL/vial, each vial contains 0.75mg of ciprofloxacin and 0.0625mg of fluocinolone acetonide.
Study NCT04636957 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ciprofloxacin 0.3% solution
Description: 0.4mL/vial, each vial contains 1.2mg ciprofloxacin
Study NCT00711997 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: DTA-H19
Description: Cohort #1: 4 mg DTA-H19 intratumorally 2 times per week for 2 weeks Cohort #2: 8 mg DTA-H19 intratumorally 2 times per week for 2 weeks
Study NCT02672397 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Additional Epidural Education
Description: All women allocated to receive additional epidural educational will be given a language appropriate pamphlet and video on neuraxial anesthesia. The video and pamphlet will be in the subject's primary language. After the subject watches the educational video they will be given an opportunity to go through the pamphlet with the research assistant and ask any questions they may have. For Spanish-speaking subjects this will occur through a telephone interpreter. The obstetric anesthesia providers and obstetricians caring for the subject will be absent for the educational video and post-video conversation.
Study NCT02314585 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Exercise
Description: Participants will partake in three, six month phases. In the second phase, either an education or exercise program will be implemented. Assessments will follow each phase with the addition of an initial assessment for baseline data.
Study NCT02314585 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Education
Description: Participants will partake in three, six month phases. In the second phase, either an education or exercise program will be implemented. Assessments will follow each phase with the addition of an initial assessment for baseline data.
Study NCT04970381 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rivaroxaban
Description: Rivaroxaban: Patients with ventricular mural thrombus in the study receive rivaroxaban anticoagulant therapy for 12 weeks. The dosage of rivaroxaban was typically 20mg once daily, or 15mg once daily if patients were on dual antiplateletagents, or with creatinine clearance of 30-50mL/min.
Study NCT03686618 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Secretin
Description: Drug to stimulate pancreatic secretion
Study NCT04531813 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Butenafine HCl 1% (BAY1896425)
Description: Approximately 0.2 g of cream containing butenafine HCl 1% daily (excluding weekends) was applied to the absorbent pad portion of a semi-occlusive dressing, which was then applied to the skin test site. The total dose applied to each participant completing the trial was 3 g.
Study NCT03864666 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: PMR 200 mg
Description: Two PMR 200 mg at 08:00, single oral dose (total daily dose of 400 mg)
Study NCT03383692 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DS-8201a
Description: DS-8201a is provided as a sterile lyophilized powder of DS-8201a in a glass vial, which will be dissolved and administered as an intravenous (IV) solution
Study NCT03383692 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ritonavir
Description: Ritonavir is a OATP1B inhibitor; an antiretroviral tablet for oral administration
Study NCT03383692 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Itraconazole
Description: Itraconazole is a CYP3A inhibitor; an antifungal tablet for oral administration
Study NCT04068740 — intervention group
Intervention type: PROCEDURE
Intervention: Surgical treatment of valvular heart disease
Description: Valve replacement or repair
Study NCT04068740 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Virtual treatment
Description: Virtual valve replacement or repair surgery
Study NCT01653327 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ketamine
Description: Twenty milligrams of ketamine will be dissolved in 4 mL of pharmaceutical cherry syrup and 1 ml of normal saline.
Study NCT04531813 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Positive Control-Sodium lauryl sulfate (SLS)
Description: Approximately 0.2 mL of 0.3% solution of sodium lauryl sulfate was applied to the absorbent pad portion of a semi-occlusive dressing, which was then applied to the Positive Control test site.
Study NCT04531813 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Negative Control
Description: A blank patch was applied to the Negative Control test site.
Study NCT01430078 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ASP015K
Description: oral tablet
Study NCT01653327 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT01430078 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ASP015K
Description: solution via oral capsule
Study NCT04061733 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Hydrogel injection
Description: Hydrogel injection
Study NCT02073656 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LDV/SOF
Description: 90/400 mg FDC tablet administered orally once daily
Study NCT02073656 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RBV
Description: Tablets administered orally in a divided daily dose according to package insert weight-based dosing recommendations (\< 75 kg = 1000 mg and ≥ 75 kg = 1200 mg)
Study NCT02431806 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matched over-encapsulated placebo capsules administered orally on Day 1 to Week 8.
Study NCT02431806 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Levomilnacipran
Description: Over-encapsulated levomilnacipran ER capsules administered orally on Day 1 to Week 8.
Study NCT02431806 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fluoxetine
Description: Over-encapsulated fluoxetine tablets administered orally on Day 1 to Week 8.
Study NCT03538067 — intervention group
Intervention type: PROCEDURE
Intervention: Percutaneous coronary intervention (PCI)
Description: Patients will undergo PCI with intravascular ultrasound (IVUS) as part of standard clinical care in accordance with operator discretion. The research protocol will be observational - using IVUS to determine the effects of balloon inflation time, balloon inflation pressure, balloon type, atherosclerotic plaque morphology on stent expansion (minimal luminal area, MLA)
Study NCT01948583 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Hyaluronic Acid
Description: Arm I: new formulation applied for the first week, formulation on the marked applied for the third week (second week - wash out period) Arm II: formulation on the marked applied for the first week, new formulation applied for the third week (second week - wash out period)
Study NCT02668159 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Fish peptide supplement
Description: 6 capsules of fish peptide supplement (3g/each) administered prior to one of the OGTT
Study NCT02668159 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Vitamin D supplement
Description: 1 tablet of vitamin D3 (1000 UI) administered prior to one of the OGTT
Study NCT02668159 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Fish peptide + Vitamin D3 supplements
Description: 6 capsules of fish peptide (3g/each) + 1 tablet of vitamin D3 (1000 UI) administered prior to one of the OGTT
Study NCT02668159 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 7 tablets of placebos administered prior to one the OGTT
Study NCT01666210 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: OTX-DP (Dexamethasone punctum plug)
Description: Sustained and tapered release of dexamethasone from hydrogel punctum plug
Study NCT01666210 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Vehicle Punctum Plug
Description: Hydrogel punctum plug without dexamethasone
Study NCT01840800 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ropivacaine
Study NCT01840800 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Study NCT03000530 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SAGE-217
Study NCT03000530 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT03743402 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Pain self-management training
Description: This intervention will have 4 components:~1. telephone-delivered evidence-based pain self-management training,~2. web-based video of successfully tapered patients with motivational interviewing debriefing,~3. a voluntary, self-paced opioid taper~4. opioid and non-opioid prescribing guidance for the patient's primary care provider.
Study NCT03743402 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: video education, motivational interviewing
Description: web-based video of successfully tapered patients with motivational interviewing debriefing
Study NCT03743402 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: voluntary self-paced opioid taper
Description: Voluntary self-paced opioid taper where patient chooses whether, when and how much to taper opioids. Taper schedule and strategy will be proposed to patients, but they will negotiate details with their primary care provider.
Study NCT03743402 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: prescribing guidance for primary care provider
Description: Based upon review of medications and diagnoses in the electronic medical record, the principal investigator will offer guidance on opioid taper rate and strategy. He will also offer suggestions to adjust or initiate other psychotropic medications to treat pain or psychiatric comorbid illness that may be unmasked through opioid taper. All prescriptions will be written by the primary care provider.
Study NCT03743402 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: usual care
Description: Usual care will consist of any and all regular care that may be offered by primary care for chronic pain and related illnesses
Study NCT01709773 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Focal treatment
Description: Focal treatment of high-grade cervical intraepithelial neoplasia using laser ablation, cryotherapy, or loop electrosurgical excision procedure
Study NCT01412892 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RAD001: Everolimus
Description: 10 mg of RAD001 will be self-administered orally once daily continuously for one year or until unacceptable toxicity or discontinuation from the study from any other reason.
Study NCT00968188 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Keep It Up!
Description: Online HIV Intervention Prevention Website tailored to Young Men that Have Sex with Men. Website is tailored to be more engaging, includes videos and games.
Study NCT00968188 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Information only
Description: Medically fact based HIV information delivered online.
Study NCT03707366 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: FHF-T
Description: FHF-T employs mentoring, consisting of relationship development, advocating for and empowering youth, and skill-building activities to promote positive youth development. Mentors meet individually for 2-3 hours per week for 30 weeks with each teen they mentor, in order to engage teens in positive youth development activities and provide skills training in areas including emotion recognition, perspective-taking, problem solving, effective communication, managing anger, healthy coping and resisting peer pressure for deviant activities. Youth also attend group workshops over the course of the program, in which they engage with other participants and mentors in skill-building activities.
Study NCT03410901 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Anti-OX40 Antibody BMS 986178
Description: Given IV, intratumoral
Study NCT03410901 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study NCT03410901 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiation Therapy
Description: Undergo radiation therapy
Study NCT03410901 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TLR9 Agonist SD-101
Description: Given intratumorally
Study NCT02805985 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: FLXfit™ TLIF Interbody Fusion Device
Description: The FLXfit™ is an expandable, articulated interbody fusion device (IBFD) used in conjunction with supplemental fixation to provide structural stability in skeletally mature individuals following total or partial discectomy.
Study NCT03245619 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK3335065
Description: GSK3335065 is being developed as a treatment for acute pancreatitis with the intent of reducing 3-hydroxykynurenine (3HK) levels to the normal range (or lower) and maintaining them at this level. GSK3335065 is a solution and will be administered as intravenous injection and infusion with dose strength of 5 milligram (mg)/mL that may be diluted in 0.9% weight by volume (w/v) sodium chloride.
Study NCT02183909 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Testing and linkage to care for Y/MSM
Description: Implementation of strategies to enhance testing and linkage to care of Y/MSM, including social network testing and a youth outreach corps working with existing and new community partner agencies.
Study NCT03245619 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo solution to match GSK3335065 will be given as intravenous injection and infusion.
Study NCT03401723 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: 3D-Colonoscopy Progression Score
Description: 3D-Colonoscopy Progression Score is a computerized analysis of the movement of the colonoscope based on data from coils within the colonoscope.